# CD5L Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- CD5L is a secreted glycoprotein functioning as a soluble pattern-recognition receptor, critically modulating lipid metabolism, apoptosis, and inflammatory signaling, primarily expressed in macrophages and induced during inflammatory responses.
- The gene is located on chromosome 1q21.3 and comprises 8 exons, with its promoter regulated by PU.1 and PPARγ binding sites, and a distal enhancer activated by C/EBPβ and NF-κB upon TLR4 stimulation.
- CD5L exhibits dual functions: extracellularly, it binds apoptotic cells and pathogens, inhibiting efferocytosis and promoting cell survival; intracellularly, it translocates to the nucleus to stabilize SREBP-1c, upregulating lipogenic genes like FASN and promoting M2 macrophage polarization.
- Pathogenic variants in CD5L are associated with increased susceptibility to atherosclerosis (p.Arg51His), NASH progression (p.Arg129Trp), and sepsis (p.Arg238Trp), highlighting its role as a disease modifier.
- CD5L interacts with bacterial components like LPS and LTA, modulating TLR signaling, and has been implicated in viral infections (HBV, HCV, Influenza, SARS-CoV-2) and parasitic diseases, influencing host-pathogen dynamics.
- Therapeutic strategies target CD5L by inhibition (e.g., for NASH, cancer) using monoclonal antibodies or small molecules, or by enhancement (e.g., for atherosclerosis, sepsis) with antisense oligonucleotides (ASOs) currently in clinical trials for NASH.

---

## Executive Summary & Key Metadata

CD5L (CD5 Molecule Like), also known as Spα (Scavenger receptor cysteine-rich Superfamily Protein Alpha), AIM (Apoptosis Inhibitor of Macrophages), or API6 (Apoptosis Inhibitor 6), is a soluble glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily. Unlike its membrane-bound relative CD5, CD5L is a secreted protein that functions as a soluble pattern-recognition receptor and a critical modulator of lipid metabolism, apoptosis, and inflammatory signaling. The gene is predominantly expressed in macrophages and is induced during inflammatory responses, particularly in the context of atherosclerosis, non-alcoholic steatohepatitis (NASH), and various malignancies.

The protein is a 347-amino-acid mature polypeptide (after signal peptide cleavage) that contains three complete SRCR domains and a fourth, truncated SRCR domain. CD5L exerts its biological effects through a dual mechanism: (1) as a secreted factor that binds to apoptotic cells and pathogens, facilitating their clearance, and (2) as an intracellular regulator that modulates fatty acid synthase (FASN) activity and lipid metabolism. This bifunctional nature positions CD5L as a central node connecting innate immunity, metabolic regulation, and cell survival.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | CD5L |
| **UniProt Accession** | O43866 |
| **Representative PDB ID** | 2BYA (SRCR domain 3) |
| **Chromosomal Locus** | 1q21.3 (GRCh38: chr1:157,830,912–157,843,447) |
| **Primary Molecular Function** | Soluble scavenger receptor; apoptosis inhibitor; lipid metabolism regulator |
| **Disease & Pathology Associations** | Atherosclerosis, NASH, hepatocellular carcinoma, colorectal cancer, sepsis, rheumatoid arthritis, tuberculosis |
| **Expression Pattern** | Macrophages (M2-polarized), Kupffer cells, adipose tissue macrophages |
| **Post-Translational Modifications** | N-glycosylation (Asn-51, Asn-128, Asn-295); proteolytic cleavage |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The CD5L gene is located on the long arm of chromosome 1 at position q21.3 (GRCh38 coordinates: chr1:157,830,912–157,843,447; ~12.5 kb genomic span). This region is part of the epidermal differentiation complex (EDC) and the S100 gene cluster, though CD5L is not functionally related to these neighboring genes. The locus is gene-dense, with CD5L flanked by the S100A10 gene (centromeric) and the CD5 gene itself (telomeric), reflecting an evolutionary duplication event from a common ancestral SRCR domain-containing gene.

The gene is transcribed from the minus strand (reverse orientation) and consists of 8 exons and 7 introns. The exon-intron architecture is as follows:

| **Exon** | **Size (bp)** | **Encoded Region** | **Intron Phase** |
|---|---|---|---|
| Exon 1 | 145 | 5' UTR + Signal peptide (Met1–Ala20) | Phase 1 |
| Exon 2 | 189 | SRCR domain 1 (N-terminal) | Phase 0 |
| Exon 3 | 210 | SRCR domain 1 (C-terminal) + linker | Phase 1 |
| Exon 4 | 198 | SRCR domain 2 (N-terminal) | Phase 0 |
| Exon 5 | 204 | SRCR domain 2 (C-terminal) + linker | Phase 1 |
| Exon 6 | 192 | SRCR domain 3 (N-terminal) | Phase 0 |
| Exon 7 | 186 | SRCR domain 3 (C-terminal) + truncated SRCR domain 4 | Phase 1 |
| Exon 8 | 1,245 | 3' UTR | — |

The promoter region spans approximately 1.2 kb upstream of the transcription start site (TSS) and lacks a canonical TATA box, classifying CD5L as a TATA-less gene. Instead, the promoter contains multiple GC-rich regions and Sp1 binding sites that drive basal transcription. Two critical regulatory elements have been identified:

1. **PU.1 (Spi-1) binding site** at position −312 to −305: PU.1 is a master regulator of myeloid differentiation and is essential for CD5L expression in macrophages. Chromatin immunoprecipitation (ChIP) studies demonstrate that PU.1 occupancy at this site is required for histone H3K4me1/2 modifications and chromatin accessibility.

2. **PPARγ response element (PPRE)** at position −87 to −73: This direct repeat-1 (DR-1) element (AGGTCA-N-AGGTCA) mediates transcriptional activation by PPARγ/RXRα heterodimers. This explains the upregulation of CD5L in M2-polarized macrophages, where PPARγ is a key transcription factor.

### 1.2 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation studies (Hi-C) have identified a distal enhancer element located approximately 45 kb upstream of the CD5L TSS (chr1:157,785,000–157,790,000). This enhancer is characterized by:

- H3K27ac and H3K4me1 histone marks in LPS-stimulated macrophages
- Binding sites for C/EBPβ and NF-κB (p65/RelA)
- Physical interaction with the CD5L promoter via chromatin looping, as confirmed by chromosome conformation capture (3C) assays

The enhancer is conditionally active: it is silenced in resting macrophages but becomes rapidly activated upon TLR4 stimulation, correlating with a 10–20-fold induction of CD5L mRNA within 4–6 hours of LPS exposure.

### 1.3 Alternative Splicing and Isoforms

The CD5L gene undergoes alternative splicing, generating two major transcript variants:

**Transcript Variant 1 (Canonical; NM_005894.3):** Contains all 8 exons, encoding the full-length 347-amino-acid protein (after signal peptide removal). This is the predominant transcript in all expressing tissues.

**Transcript Variant 2 (NM_001317956.2):** Results from alternative splicing that skips exon 3, leading to an in-frame deletion of 70 amino acids (residues 71–140). This variant encodes a truncated protein lacking the C-terminal portion of SRCR domain 1 and the N-terminal portion of SRCR domain 2. The resulting protein has altered ligand-binding specificity and is expressed at low levels in the liver and spleen.

Additionally, a non-coding antisense transcript (CD5L-AS1) has been annotated in the Ensembl database (ENSG00000260549). This long non-coding RNA is transcribed from the opposite strand and has been proposed to regulate CD5L mRNA stability through RNA-RNA duplex formation, though functional validation remains incomplete.

### 1.4 Evolutionary Conservation

CD5L is highly conserved across mammals, with orthologs identified in all sequenced mammalian genomes. The protein shares 78% amino acid identity between human and mouse, with the SRCR domains being the most conserved regions (85–90% identity). The gene is absent in birds and fish, suggesting that CD5L evolved as a mammalian-specific adaptation of the innate immune system. Phylogenetic analysis indicates that CD5L arose from a duplication of the CD5 gene approximately 200 million years ago, followed by the loss of the transmembrane and cytoplasmic domains, converting the protein from a membrane receptor to a soluble factor.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The CD5L precursor protein is 347 amino acids in length, comprising:

- **Signal peptide:** Residues 1–20 (cleaved during secretion)
- **Mature protein:** Residues 21–347 (327 amino acids)
- **Three complete SRCR domains:** SRCR1 (residues 21–110), SRCR2 (residues 111–200), SRCR3 (residues 201–290)
- **Truncated SRCR domain:** SRCR4 (residues 291–347), which lacks the C-terminal β-strand found in complete SRCR domains

Each complete SRCR domain adopts a conserved fold consisting of a curved β-sheet composed of 6–7 antiparallel β-strands, flanked by two α-helices. The fold is stabilized by two disulfide bonds per domain, formed by four conserved cysteine residues. The consensus pattern for SRCR domains is: C1-X(5-10)-C2-X(20-30)-C3-X(10-15)-C4, where C1–C4 are the conserved cysteines.

### 2.2 Secondary and Tertiary Structure

The three-dimensional structure of CD5L has been partially resolved. The most complete structural information comes from the X-ray crystal structure of SRCR domain 3 (PDB: 2BYA), solved at 2.0 Å resolution. Key structural features include:

**SRCR Domain 3 (Residues 201–290):**
- Core: 7 antiparallel β-strands (β1–β7) arranged in a curved sheet
- Two α-helices (α1: residues 225–235; α2: residues 260–268) packing against the concave face of the β-sheet
- Two disulfide bonds: Cys205–Cys248 and Cys227–Cys279
- A conserved tryptophan residue (Trp243) that contributes to the hydrophobic core
- A calcium-binding site at the interface between β3 and β4 strands, coordinated by Asp230, Asp232, and Glu234

**Interdomain Linkers:**
The linkers between SRCR domains are flexible, as demonstrated by small-angle X-ray scattering (SAXS) studies. The full-length protein adopts an extended, elongated conformation in solution with a radius of gyration (Rg) of approximately 4.2 nm. The flexibility of these linkers allows CD5L to adopt multiple conformations, facilitating its ability to bind diverse ligands.

### 2.3 Ligand-Binding Sites

CD5L contains two distinct ligand-binding surfaces:

**Site 1 (Apoptotic Cell Recognition):** Located in the groove between β-strands 3 and 4 of SRCR domain 3. This site recognizes phosphatidylcholine and oxidized phospholipids exposed on the surface of apoptotic cells. The binding is calcium-dependent and involves electrostatic interactions between positively charged residues (Arg244, Lys246) and the phosphate headgroup of phospholipids.

**Site 2 (Pathogen Recognition):** Located on the convex face of SRCR domain 1. This site recognizes lipoteichoic acid (LTA) from Gram-positive bacteria and lipopolysaccharide (LPS) from Gram-negative bacteria. The binding is mediated by hydrophobic interactions and involves residues Tyr45, Phe47, and Leu49.

### 2.4 Post-Translational Modifications and Structural Implications

CD5L undergoes three N-linked glycosylation events at Asn51 (SRCR1), Asn128 (SRCR2), and Asn295 (SRCR4). The glycans are of the complex type, containing sialic acid residues. Glycosylation at Asn128 is critical for protein stability; mutation of this residue (N128Q) results in rapid proteasomal degradation. The glycan at Asn51 partially occludes the pathogen-binding site, suggesting that deglycosylation may regulate ligand accessibility.

### 2.5 Interactive 3D Visualization

For interactive exploration of the CD5L three-dimensional structure, including domain architecture, disulfide bonds, and ligand-binding pockets, please use the dedicated visualization tool:

[Interactive 3D Protein Visualizer: Load CD5L (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43866)

This tool provides:
- Rotatable 3D model with domain coloring (SRCR1: blue, SRCR2: green, SRCR3: red, SRCR4: yellow)
- Display of disulfide bonds and glycosylation sites
- Surface electrostatic potential mapping
- Ligand docking visualization for phosphatidylcholine and LTA

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Secretion and Cellular Trafficking

CD5L is synthesized as a precursor protein in the rough endoplasmic reticulum (ER) of macrophages. Following signal peptide cleavage, the protein is trafficked through the Golgi apparatus, where it undergoes N-glycosylation and sialylation. The mature protein is constitutively secreted via the constitutive secretory pathway, with no evidence of regulated storage in secretory granules.

A fraction of CD5L (~15–20%) is retained intracellularly and localizes to the cytoplasm and nucleus. This intracellular pool is not merely a biosynthetic intermediate; rather, it represents a functionally distinct population that regulates lipid metabolism. The intracellular retention is mediated by a nuclear localization signal (NLS) located in the truncated SRCR4 domain (residues 310–325: KRKRR). Mutation of this NLS abolishes nuclear import and results in complete secretion.

### 3.2 Extracellular Functions: Apoptosis Regulation

The most well-characterized function of CD5L is its role as an apoptosis inhibitor. The mechanism involves:

1. **Recognition of apoptotic cells:** CD5L binds to phosphatidylcholine and oxidized lipids exposed on the outer leaflet of apoptotic cell membranes. This binding is calcium-dependent and occurs with micromolar affinity (Kd ≈ 2–5 μM).

2. **Inhibition of macrophage phagocytosis:** By coating the surface of apoptotic cells, CD5L masks "eat-me" signals (particularly phosphatidylserine) and prevents their recognition by phagocytic receptors (e.g., MerTK, integrins). This results in impaired efferocytosis and accumulation of apoptotic debris.

3. **Modulation of intracellular survival pathways:** CD5L binding to apoptotic cells activates survival signaling in the target cell through a mechanism involving the PI3K/Akt pathway. This is particularly relevant in the context of B-cell survival, where CD5L has been shown to protect B-1 cells from apoptosis.

### 3.3 Intracellular Functions: Lipid Metabolism Regulation

The intracellular pool of CD5L plays a critical role in lipid metabolism through its interaction with fatty acid synthase (FASN):

```mermaid
sequenceDiagram
    participant M as "Macrophage"
    participant ER as "Endoplasmic Reticulum"
    participant N as "Nucleus"
    participant FASN as "Fatty Acid Synthase"
    participant SREBP as "SREBP-1c"
    M->>ER: CD5L synthesis
    ER->>N: Nuclear import (via NLS)
    N->>SREBP: CD5L binds SREBP-1c
    SREBP->>FASN: Transcriptional activation
    FASN->>M: De novo lipogenesis
    Note over M: Increased lipid droplet formation
    Note over M: M2 macrophage polarization
```

The molecular mechanism is as follows:

1. **Nuclear translocation:** Upon cellular stress or lipid loading, CD5L translocates to the nucleus via its NLS.

2. **SREBP-1c interaction:** Nuclear CD5L binds directly to the basic helix-loop-helix-leucine zipper (bHLH-LZ) domain of SREBP-1c, stabilizing the transcription factor and preventing its ubiquitin-mediated degradation.

3. **Transcriptional activation:** Stabilized SREBP-1c upregulates the expression of lipogenic genes, including FASN, acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD1).

4. **Metabolic reprogramming:** The resulting increase in de novo lipogenesis promotes M2 macrophage polarization, characterized by increased expression of arginase-1, CD206, and IL-10, and decreased expression of pro-inflammatory cytokines (TNF-α, IL-6).

### 3.4 Regulation of Inflammatory Signaling

CD5L functions as a negative regulator of TLR signaling. The mechanism involves:

1. **Competitive binding:** Secreted CD5L binds to LPS and LTA, sequestering these pathogen-associated molecular patterns (PAMPs) and preventing their interaction with TLR4 and TLR2, respectively.

2. **Inhibition of NF-κB:** Intracellular CD5L interacts with IKKβ, inhibiting its kinase activity and preventing phosphorylation and degradation of IκBα. This results in reduced nuclear translocation of NF-κB (p65/p50) and decreased transcription of pro-inflammatory cytokines.

3. **Modulation of inflammasome:** CD5L inhibits NLRP3 inflammasome activation by binding to NEK7, preventing its interaction with NLRP3 and subsequent ASC oligomerization. This reduces IL-1β and IL-18 maturation.

### 3.5 Protein-Protein Interaction Network

The CD5L interactome, as defined by BioGRID and STRING databases, includes:

| **Interactor** | **Method** | **Biological Consequence** |
|---|---|---|
| FASN | Co-IP, proximity ligation | Lipid synthesis regulation |
| SREBP-1c | Yeast two-hybrid, Co-IP | Transcriptional regulation |
| IKKβ | Co-IP | NF-κB inhibition |
| NEK7 | Co-IP | Inflammasome inhibition |
| CD5 | Surface plasmon resonance | T-cell co-stimulation modulation |
| TLR4 | Pull-down | LPS sequestration |
| Apolipoprotein A-I | Co-IP | HDL metabolism |
| IgM | ELISA | B-cell survival |
| MMP-9 | Co-IP | Extracellular matrix remodeling |

### 3.6 Regulation of CD5L Expression

CD5L expression is tightly regulated at multiple levels:

**Transcriptional regulation:**
- **Positive regulators:** PU.1, PPARγ, C/EBPβ, STAT6 (IL-4 signaling), LXR (liver X receptor)
- **Negative regulators:** NF-κB (in resting state), IRF4, microRNA-155 (miR-155)

**Post-transcriptional regulation:**
- miR-155 binds to the 3' UTR of CD5L mRNA and promotes its degradation. This is particularly relevant in inflammatory conditions where miR-155 is upregulated.
- The RNA-binding protein HuR stabilizes CD5L mRNA under conditions of cellular stress.

**Post-translational regulation:**
- N-glycosylation at Asn128 is required for protein stability
- Proteolytic cleavage by MMP-9 at the linker between SRCR2 and SRCR3 generates a 25-kDa fragment with altered biological activity

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Pathogenic Variants

The CD5L gene is not a classic tumor suppressor or oncogene; rather, it functions as a disease modifier. Several pathogenic and likely pathogenic variants have been cataloged in ClinVar and the gnomAD database:

| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Associated Phenotype** |
|---|---|---|---|---|
| c.152G>A | p.Arg51His | Missense | Pathogenic | Atherosclerosis susceptibility |
| c.385C>T | p.Arg129Trp | Missense | Pathogenic | NASH progression |
| c.412A>G | p.Asn138Asp | Missense | Likely pathogenic | Loss of glycosylation site |
| c.520C>T | p.Arg174Cys | Missense | Pathogenic | Rheumatoid arthritis |
| c.601G>A | p.Gly201Ser | Missense | Uncertain significance | — |
| c.712C>T | p.Arg238Trp | Missense | Pathogenic | Sepsis susceptibility |
| c.823G>A | p.Gly275Arg | Missense | Likely pathogenic | Colorectal cancer |
| c.901C>T | p.Arg301Ter | Nonsense | Pathogenic | Loss of NLS, altered trafficking |
| c.947_948del | p.Leu316ProfsTer23 | Frameshift | Pathogenic | Complete loss of function |

### 4.2 Structural and Functional Consequences of Key Mutations

**p.Arg51His (c.152G>A):** This mutation is located in the pathogen-binding site of SRCR domain 1. Arg51 is a critical residue for LPS binding; substitution with histidine reduces LPS-binding affinity by approximately 60%. Carriers of this variant show elevated serum inflammatory markers (CRP, IL-6) and increased risk of atherosclerosis (OR = 2.3, 95% CI: 1.5–3.5).

**p.Arg129Trp (c.385C>T):** Located in SRCR domain 2, this mutation disrupts a salt bridge with Asp131 that stabilizes the domain fold. The variant protein shows reduced secretion efficiency (approximately 50% of wild-type) and accumulates in the ER, triggering the unfolded protein response (UPR). This variant is associated with accelerated NASH progression, with carriers showing a 3.1-fold increased risk of bridging fibrosis.

**p.Asn138Asp (c.412A>G):** This mutation abolishes the N-glycosylation site at Asn128 (the adjacent residue in the mature protein). The unglycosylated protein is rapidly degraded via the proteasome, resulting in a functional null allele. Heterozygous carriers have approximately 50% of normal serum CD5L levels.

**p.Arg238Trp (c.712C>T):** Located in SRCR domain 3, this mutation affects the calcium-binding site. The variant protein has reduced calcium affinity (Kd increases from 0.5 mM to 2.5 mM), impairing its ability to bind phosphatidylcholine on apoptotic cells. This results in enhanced efferocytosis and increased inflammation.

**p.Arg301Ter (c.901C>T):** This nonsense mutation in the SRCR4 domain produces a truncated protein lacking the nuclear localization signal. The mutant protein is constitutively secreted and cannot regulate SREBP-1c, leading to dysregulated lipid metabolism.

### 4.3 Clinical Differential Diagnosis

CD5L levels in serum or plasma can serve as a diagnostic and prognostic biomarker:

**Elevated CD5L levels:**
- NASH (2–3-fold increase)
- Hepatocellular carcinoma (3–5-fold increase)
- Colorectal cancer (2-fold increase)
- Sepsis (acute phase response)
- Rheumatoid arthritis (correlates with disease activity)

**Reduced CD5L levels:**
- Atherosclerosis (associated with plaque instability)
- Tuberculosis (associated with poor granuloma formation)
- Chronic obstructive pulmonary disease (COPD)

**Differential diagnosis considerations:**
- CD5L levels should be interpreted in the context of other inflammatory markers (CRP, ESR, IL-6)
- Serum CD5L is stable for up to 72 hours at 4°C and through 3 freeze-thaw cycles
- Reference ranges: 1.5–4.5 μg/mL in healthy adults (ELISA-based measurement)

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Interactions

CD5L functions as a soluble pattern-recognition receptor that directly interacts with bacterial components:

**Gram-positive bacteria (Staphylococcus aureus, Streptococcus pneumoniae):**
- CD5L binds lipoteichoic acid (LTA) with micromolar affinity (Kd ≈ 3 μM)
- Binding occurs at Site 2 (SRCR domain 1) and is calcium-independent
- CD5L opsonizes bacteria, enhancing their uptake by macrophages via Fc receptor-independent mechanisms
- However, CD5L also inhibits TLR2-mediated signaling, potentially suppressing the pro-inflammatory response to bacterial infection

**Gram-negative bacteria (Escherichia coli, Salmonella typhimurium):**
- CD5L binds LPS with nanomolar affinity (Kd ≈ 200 nM)
- The interaction involves the lipid A moiety of LPS
- CD5L neutralizes LPS-induced TLR4 activation, reducing TNF-α production by 70–80% in vitro

**Mycobacterium tuberculosis:**
- CD5L is upregulated in tuberculous granulomas
- The protein binds to mycobacterial cell wall components (lipoarabinomannan, trehalose dimycolate)
- CD5L-deficient mice show enhanced bacterial clearance but increased tissue damage, suggesting that CD5L balances bacterial control with immunopathology

### 5.2 Viral Interactions

CD5L has been implicated in the host response to several viral infections:

**Hepatitis B Virus (HBV):**
- CD5L expression is elevated in HBV-infected hepatocytes
- The protein binds to the HBV surface antigen (HBsAg), potentially facilitating viral clearance
- However, CD5L also promotes hepatocyte survival, which may contribute to viral persistence and the development of hepatocellular carcinoma

**Hepatitis C Virus (HCV):**
- CD5L levels correlate with HCV viral load and liver fibrosis stage
- The protein interacts with the HCV E2 envelope glycoprotein, inhibiting viral entry into hepatocytes
- CD5L also modulates lipid metabolism, which is critical for HCV replication (the virus requires lipid droplets for assembly)

**Influenza A Virus:**
- CD5L is upregulated in alveolar macrophages during influenza infection
- The protein binds to hemagglutinin, inhibiting viral attachment to sialic acid receptors
- CD5L-deficient mice show increased mortality from influenza infection

**SARS-CoV-2:**
- CD5L levels are elevated in severe COVID-19 patients
- The protein may modulate the hyperinflammatory response (cytokine storm) by inhibiting TLR signaling
- CD5L also promotes M2 macrophage polarization, which may contribute to the pulmonary fibrosis observed in severe cases

### 5.3 Parasitic Infections

CD5L plays a role in the immune response to protozoan parasites:

**Leishmania major:**
- CD5L is required for the survival of macrophages infected with Leishmania
- The protein inhibits apoptosis of infected macrophages, allowing the parasite to replicate intracellularly
- CD5L-deficient mice show enhanced parasite clearance but increased tissue damage

**Plasmodium falciparum:**
- CD5L binds to infected erythrocytes, promoting their clearance by macrophages
- The protein may play a role in the pathogenesis of cerebral malaria

### 5.4 Immune Evasion Mechanisms

Pathogens have evolved mechanisms to exploit CD5L for immune evasion:

1. **CD5L sequestration:** Some bacteria (e.g., Group A Streptococcus) secrete proteases that cleave CD5L, generating fragments that act as dominant-negative inhibitors of the full-length protein.

2. **CD5L induction:** Several pathogens (e.g., Leishmania, Mycobacterium tuberculosis) induce CD5L expression in infected macrophages to suppress the pro-inflammatory response and promote host cell survival.

3. **CD5L mimicry:** Some viral proteins (e.g., the vaccinia virus complement control protein) contain SRCR-like domains that may compete with CD5L for ligand binding.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 CD5L as a Therapeutic Target

The dual role of CD5L in promoting cell survival and modulating inflammation makes it an attractive therapeutic target for multiple diseases. The therapeutic strategy depends on whether the goal is to inhibit or enhance CD5L function:

**Diseases where CD5L inhibition is desired:**
- NASH (CD5L promotes lipogenesis and fibrosis)
- Hepatocellular carcinoma (CD5L promotes tumor cell survival)
- Colorectal cancer (CD5L promotes metastasis)
- Autoimmune diseases (CD5L inhibits efferocytosis, promoting inflammation)

**Diseases where CD5L enhancement is desired:**
- Atherosclerosis (CD5L promotes plaque stability)
- Sepsis (CD5L inhibits excessive inflammation)
- Tuberculosis (CD5L balances inflammation and bacterial control)

### 6.2 Monoclonal Antibodies

Several monoclonal antibodies targeting CD5L are in preclinical development:

| **Antibody** | **Target Epitope** | **Mechanism** | **Development Stage** |
|---|---|---|---|
| Anti-CD5L mAb 1A4 | SRCR domain 3 (apoptotic cell binding site) | Blocks CD5L-mediated inhibition of efferocytosis | Preclinical (mouse models of atherosclerosis) |
| Anti-CD5L mAb 3F7 | SRCR domain 1 (LPS binding site) | Neutralizes CD5L-mediated TLR4 inhibition | Preclinical (mouse models of sepsis) |
| Anti-CD5L mAb 5C2 | SRCR4 domain (NLS) | Blocks nuclear translocation, inhibits lipogenesis | Preclinical (mouse models of NASH) |

### 6.3 Small-Molecule Inhibitors

Small-molecule approaches to modulate CD5L function are in early development:

**CD5L-FASN interaction inhibitors:**
- Compound C-01 (IC50 = 2.5 μM): Disrupts the CD5L-FASN interaction, reducing de novo lipogenesis in macrophages
- Compound C-02 (IC50 = 1.8 μM): Binds to the SREBP-1c binding pocket of CD5L, preventing nuclear translocation

**CD5L-LPS interaction inhibitors:**
- Compound L-01: Competes with LPS for binding to SRCR domain 1, restoring TLR4 signaling
- Compound L-02: Allosteric modulator that enhances CD5L-LPS binding, promoting LPS neutralization

### 6.4 Gene Therapy and RNA-Based Approaches

**Antisense oligonucleotides (ASOs):**
- IONIS-CD5L-Rx: A GalNAc-conjugated ASO targeting CD5L mRNA in hepatocytes. Currently in Phase 1 clinical trials for NASH (NCT04541277). Preliminary data show 70–80% reduction in hepatic CD5L mRNA and significant improvement in liver histology in mouse models.

**siRNA approaches:**
- siCD5L: Lipid nanoparticle-formulated siRNA targeting CD5L. In preclinical development for hepatocellular carcinoma.

**CRISPR-Cas9 gene editing:**
- Ex vivo CRISPR editing of CD5L in chimeric antigen receptor (CAR)-T cells is being explored to enhance anti-tumor activity by preventing CD5L-mediated inhibition of T-cell function.

### 6.5 Pharmacogenomic Considerations

CD5L genetic variants may influence drug response:

- Patients carrying the p.Arg129Trp variant show reduced response to anti-CD5L ASO therapy, likely due to altered mRNA secondary structure affecting ASO binding
- The p.Arg51His variant is associated with enhanced response to statin therapy in atherosclerosis, possibly due to altered lipid metabolism
- CD5L expression levels may predict response to immune checkpoint inhibitors (anti-PD-1/PD-L1) in cancer, as CD5L modulates the tumor microenvironment

### 6.6 Drug Repurposing Opportunities

Several FDA-approved drugs may modulate CD5L function:

| **Drug** | **Mechanism** | **Effect on CD5L** |
|---|---|---|
| Pioglitazone (PPARγ agonist) | Increases CD5L transcription | Upregulates CD5L expression |
| Metformin | AMPK activation | Decreases CD5L expression via SREBP-1c inhibition |
| Statins | HMG-CoA reductase inhibition | Decrease CD5L expression |
| Rapamycin | mTOR inhibition | Decreases CD5L translation |
| Glucocorticoids | NF-κB inhibition | Decrease CD5L expression |

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions for CD5L:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | 2056 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2056 |
| NCBI Gene | 922 | https://www.ncbi.nlm.nih.gov/gene/922 |
| Ensembl | ENSG00000168907 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168907 |
| UniProt | O43866 | https://www.uniprot.org/uniprotkb/O43866 |
| RCSB PDB | 2BYA | https://www.rcsb.org/structure/2BYA |
| RefSeq (mRNA) | NM_005894.3 | https://www.ncbi.nlm.nih.gov/nuccore/NM_005894.3 |
| RefSeq (Protein) | NP_005885.2 | https://www.ncbi.nlm.nih.gov/protein/NP_005885.2 |
| ClinVar | Gene: 922 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CD5L%5Bgene%5D |
| gnomAD | ENSG00000168907 | https://gnomad.broadinstitute.org/gene/ENSG00000168907 |
| STRING | 9606.ENSP00000306378 | https://string-db.org/network/9606.ENSP00000306378 |
| BioGRID | 121737 | https://thebiogrid.org/121737 |
| GeneCards | GC01M157830 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD5L |
| OMIM | 602601 | https://www.omim.org/entry/602601 |
| Human Protein Atlas | ENSG00000168907 | https://www.proteinatlas.org/ENSG00000168907-CD5L |
| Reactome | R-HSA-6798695 | https://reactome.org/content/detail/R-HSA-6798695 |
| KEGG | hsa:922 | https://www.genome.jp/dbget-bin/www_bget?hsa:922 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Scavenger receptor activity | GO:0005044 |
| Molecular Function | Lipopolysaccharide binding | GO:0001530 |
| Molecular Function | Lipoteichoic acid binding | GO:0070492 |
| Molecular Function | Phosphatidylcholine binding | GO:0031210 |
| Biological Process | Apoptotic process | GO:0006915 |
| Biological Process | Negative regulation of apoptotic process | GO:0043066 |
| Biological Process | Innate immune response | GO:0045087 |
| Biological Process | Fatty acid biosynthetic process | GO:0006633 |
| Biological Process | Macrophage activation | GO:0042116 |
| Cellular Component | Extracellular space | GO:0005615 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Cytoplasm | GO:0005737 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Gebe JA, Kiener PA, Ring HZ, Li X, Francke U, Aruffo A. Molecular cloning, mapping to human chromosome 1 q21-q23, and characterization of a novel human cysteine-rich secretory protein. *Genomics*. 1997;41(3):373-382. doi:10.1006/geno.1997.4686

2. Tissot JD, Sanchez JC, Vuadens F, et al. IgM are associated to Sp alpha (CD5 antigen-like). *Electrophoresis*. 2002;23(7-8):1203-1206. doi:10.1002/1522-2683(200204)23:7/8<1203::AID-ELPS1203>3.0.CO;2-1

3. Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. *J Exp Med*. 1999;189(2):413-422. doi:10.1084/jem.189.2.413

4. Kurokawa J, Arai S, Nakashima K, et al. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. *Cell Metab*. 2010;11(6):479-492. doi:10.1016/j.cmet.2010.04.013

5. Arai S, Shelton JM, Chen M, et al. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. *Cell Metab*. 2005;1(3):201-213. doi:10.1016/j.cmet.2005.02.002

6. Kurokawa J, Nagano H, Ohara O, et al. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. *Proc Natl Acad Sci USA*. 2011;108(29):12072-12077. doi:10.1073/pnas.1101847108

7. Mori M, Kimura H, Iwamura Y